Managing HIV Drug Resistance
The Latest
This Week in HIV Research: How to Fix Our Dwindling HIV Workforce
April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.
This Week in HIV Research: Our Attunement to Aging
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
This Week in HIV Research: Resistance (Testing) Is Futile
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
DAWNING Study Casts New Light on the Details of Resistance
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
This Week in HIV Research: Weighing Anchor on NRTI-Free Treatment
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
CDC Study Reinforces the Importance of Annual STI Testing Among MSM
Rectal and throat tests matter too, and providers should be recommending them.
Antiviral Stewardship Program Reduces Medication Errors at a Veterans Affairs Hospital
When people living with HIV are admitted to a hospital, they may not be able to bring their medications with them, and could be prescribed new medication by a doctor who doesn't understand their complete medical history.
This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
This Week in HIV Research: Exorcizing Our PrEP Demons
Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.